AlphaCore Capital’s GSK GSK Stock Holding History

AlphaCore Capital’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$588K	Sell	10,572 -10,646	-50%	-$577K	0.01%	505
2025 Q4	$1.05M	Sell	21,218 -582	-3%	-$27.1K	0.02%	408
2025 Q3	$950K	Buy	21,800 +8,807	+68%	+$344K	0.03%	311
2025 Q2	$505K	Buy	12,993 +2,386	+22%	+$91.2K	0.02%	368
2025 Q1	$415K	Buy	10,607 +590	+6%	+$21.6K	0.04%	302
2024 Q4	$339K	Sell	10,017 -3,626	-27%	-$131K	0.07%	159
2024 Q3	$563K	Sell	13,643 -465	-3%	-$19K	0.13%	108
2024 Q2	$548K	Buy	14,108 +467	+3%	+$19.6K	0.13%	98
2024 Q1	$590K	Buy	13,641 +17	+0.1%	+$701	0.16%	87
2023 Q4	$511K	Sell	13,624 -2,713	-17%	-$97.4K	0.07%	140
2023 Q3	$592K	Buy	16,337 +1	+0%	+$35	0.09%	132
2023 Q2	$582K	Buy	+16,336	New	+$586K	0.09%	131
2020 Q2	–	Sell	-98	Closed	-$5K	–	173
2020 Q1	$5K	Buy	+98	New	+$5.23K	﹤0.01%	254

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

AlphaCore Capital's GSK Position: Q1 2026 in Review

AlphaCore Capital reduced its GSK (GSK) stake by 50% in Q1 2026, selling an estimated $577K and leaving 10,572 shares worth $588K. The position accounts for 0.01% of the portfolio, ranked #505.

AlphaCore Capital first reported a position in GSK in Q1 2020 and has held it in 13 quarters since. The position peaked at $1.05M in Q4 2025. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

AlphaCore Capital held 10,572 shares of GSK worth $588K as of Q1 2026.
AlphaCore Capital sold 10,646 GSK shares in Q1 2026, an estimated $577K.
GSK made up 0.01% of AlphaCore Capital's portfolio in Q1 2026, its #505 holding.
AlphaCore Capital first reported a position in GSK in Q1 2020 and has held it in 13 quarters since.
AlphaCore Capital's GSK position peaked at $1.05M in Q4 2025.
1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on AlphaCore Capital's 13F filing for Q1 2026, filed 15 May 2026.